… minimally pretreated patient with non-small cell lung cancer (NSCLC). Stable disease for
4-7… and non-small cell lung cancers. Analysis of normal skin and tumor biopsies is under way …

… Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine …
patients with non–small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to …

… erlotinib … Lung Cancer Symptom Scale). Sample size of 1050 was based on 80% power to
detect a 25% benefit in OS, α=0.05. Results: 1059 pts were randomized / treated (526 erlotinib…

… treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy
… non-small-cell lung cancer. Lung cancer has been estimated to be the leading cause of …

… Lung cancer is the leading cause of cancer death among men and women in North America.
In advanced non–small-cell lung cancer… for non–small-cell lung cancer. However, there is at …

… Therapeutic exposure of cancer cells to an anti-cancer agent would be considered as a … as
a cancer survival mechanism. In this study, we investigated the effect of erlotinib treatment on …

… Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. A … Erlotinib hydrochloride
salt has an equilibrium solubility of … Erlotinib hydrochloride is slightly soluble in methanol, and …

… Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor …
with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy …

… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …

… been described for the synthesis of erlotinib hydrochloride, as a useful drug in treatment of
non-small-cell lung cancer. Method: Erlotinib hydrochloride was synthesized in seven steps …